NS3 GT5
Download full data set for GT5
Asunaprevir
| Mutation | EC50 (nM) | Fold-shift | Phenotype | Clinical RAS | Reference | Comments |
| WT (SA13) | 1.7 | 1x | likely susceptible | | 1 | |
| V36M | | | | | | |
| V36A | | | | | | |
| V36L | | | | | | |
| Q41R | | | | | | |
| F43S | | | | | | |
| T54A | | | | | | |
| V55A | | | | | | |
| Y56H | | | | | | |
| Y56F | | | | | | |
| Q80H | | | | | | |
| Q80K | | | | | | |
| Q80L | | | | | | |
| Q80M | | | | | | |
| Q80I | | | | | | |
| Q80R | | | | | | |
| V107I | | | | | | |
| T122A | | | | | | |
| T122G | | | | | | |
| T122R | | | | | | |
| T122V | | | | | | |
| R155G | | | | | | |
| R155K | | | | | | |
| R155T | | | | | | |
| R155W | | | | | | |
| A156G | | | | | | |
| A156S | | | | | | |
| A156T | | | | | | |
| A156V | | | | | | |
| A166S | | | | | | |
| D168A | | | | | | |
| D168E | | | | | | |
| D168F | | | | | | |
| D168G | | | | | | |
| D168H | | | | | | |
| D168I | | | | | | |
| D168K | | | | | | |
| D168L | | | | | | |
| D168N | | | | | | |
| D168R | | | | | | |
| D168T | | | | | | |
| D168V | | | | | | |
| D168Y | | | | | | |
| I170A | | | | | | |
| I170T | | | | | | |
| I170V | | | | | | |
| V36A+Q41R | | | | | | |
| V36A+T122N | | | | | | |
| V36M+R155K | | | | | | |
| Y56H+D168A | | | | | | |
| Y56H+D168V | | | | | | |
| T122N+D168A | | | | | | |
| Q41R+D168H | | | | | | |
| Q41R+D168A | | | | | | |
| Q41R+T122N | | | | | | |
| Q41R+D168Y | | | | | | |
| G50K+T122N | | | | | | |
| 1. Sunvepra Canadian Prodcut Monograph 2016 |
Not indicated in Canada
Glecaprevir
| Mutation | EC50 (nM) | Fold-shift | Phenotype | Clinical RAS | Reference | Comments |
| WT (SA13) | 0.096 | 1x | likely susceptible | | 1 | |
| V36M | | | | | | |
| V36A | | | | | | |
| V36L | | | | | | |
| Q41R | | | | | | |
| F43S | | | | | | |
| T54A | | | | | | |
| V55A | | | | | | |
| Y56H | | | | | | |
| Y56F | | | | | | |
| Q80H | | | | | | |
| Q80K | | | | | | |
| Q80L | | | | | | |
| Q80M | | | | | | |
| Q80I | | | | | | |
| Q80R | | | | | | |
| V107I | | | | | | |
| T122A | | | | | | |
| T122G | | | | | | |
| T122R | | | | | | |
| T122V | | | | | | |
| R155G | | | | | | |
| R155K | | | | | | |
| R155T | | | | | | |
| R155W | | | | | | |
| A156G | | | | | | |
| A156S | | | | | | |
| A156T | | | | | | |
| A156V | | | | | | |
| A166S | | | | | | |
| D168A | | | | | | |
| D168E | 0.409 | 4.2x | resistance likely | yes | 1,2 | Clinical VF |
| D168F | | | | | | |
| D168G | | | | | | |
| D168H | | | | | | |
| D168I | | | | | | |
| D168K | | | | | | |
| D168L | | | | | | |
| D168N | | | | | | |
| D168R | | | | | | |
| D168T | | | | | | |
| D168V | | | | | | |
| D168Y | | | | | | |
| I170A | | | | | | |
| I170T | | | | | | |
| I170V | | | | | | |
| V36A+Q41R | | | | | | |
| V36A+T122N | | | | | | |
| V36M+R155K | | | | | | |
| Y56H+D168A | | | | | | |
| Y56H+D168V | | | | | | |
| T122N+D168A | | | | | | |
| Q41R+D168H | | | | | | |
| Q41R+D168A | | | | | | |
| Q41R+T122N | | | | | | |
| Q41R+D168Y | | | | | | |
| G50K+T122N | | | | | | |
| 1. FDA Microbiology Review https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209394Orig1s000MicroR.pdf |
| 2. Asselah T, et al. 2018. Journal of Hepatology 68: S39 |
Grazoprevir
| Mutation | EC50 (nM) | Fold-shift | Phenotype | Clinical RAS | Reference | Comments |
| WT (SA13) | | | | | | |
| V36M | | | | | | |
| V36A | | | | | | |
| V36L | | | | | | |
| Q41R | | | | | | |
| F43S | | | | | | |
| T54A | | | | | | |
| V55A | | | | | | |
| Y56H | | | | | | |
| Y56F | | | | | | |
| Q80H | | | | | | |
| Q80K | | | | | | |
| Q80L | | | | | | |
| Q80M | | | | | | |
| Q80I | | | | | | |
| Q80R | | | | | | |
| V107I | | | | | | |
| T122A | | | | | | |
| T122G | | | | | | |
| T122R | | | | | | |
| T122V | | | | | | |
| R155G | | | | | | |
| R155K | | | | | | |
| R155T | | | | | | |
| R155W | | | | | | |
| A156G | | | | | | |
| A156S | | | | | | |
| A156T | | | | | | |
| A156V | | | | | | |
| A166S | | | | | | |
| D168A | | | | | | |
| D168E | | | | | | |
| D168F | | | | | | |
| D168G | | | | | | |
| D168H | | | | | | |
| D168I | | | | | | |
| D168K | | | | | | |
| D168L | | | | | | |
| D168N | | | | | | |
| D168R | | | | | | |
| D168T | | | | | | |
| D168V | | | | | | |
| D168Y | | | | | | |
| I170A | | | | | | |
| I170T | | | | | | |
| I170V | | | | | | |
| V36A+Q41R | | | | | | |
| V36A+T122N | | | | | | |
| V36M+R155K | | | | | | |
| Y56H+D168A | | | | | | |
| Y56H+D168V | | | | | | |
| T122N+D168A | | | | | | |
| Q41R+D168H | | | | | | |
| Q41R+D168A | | | | | | |
| Q41R+T122N | | | | | | |
| Q41R+D168Y | | | | | | |
| G50K+T122N | | | | | | |
Not indicated in Canada
Paritaprevir
| | EC50 (nM) | Fold-shift | Phenotype | Clinical RAS | Reference | Comments |
| WT (SA13) | | | | | | |
| V36M | | | | | | |
| V36A | | | | | | |
| V36L | | | | | | |
| Q41R | | | | | | |
| F43S | | | | | | |
| T54A | | | | | | |
| V55A | | | | | | |
| Y56H | | | | | | |
| Y56F | | | | | | |
| Q80H | | | | | | |
| Q80K | | | | | | |
| Q80L | | | | | | |
| Q80M | | | | | | |
| Q80I | | | | | | |
| Q80R | | | | | | |
| V107I | | | | | | |
| T122A | | | | | | |
| T122G | | | | | | |
| T122R | | | | | | |
| T122V | | | | | | |
| R155G | | | | | | |
| R155K | | | | | | |
| R155T | | | | | | |
| R155W | | | | | | |
| A156G | | | | | | |
| A156S | | | | | | |
| A156T | | | | | | |
| A156V | | | | | | |
| A166S | | | | | | |
| D168A | | | | | | |
| D168E | | | | | | |
| D168F | | | | | | |
| D168G | | | | | | |
| D168H | | | | | | |
| D168I | | | | | | |
| D168K | | | | | | |
| D168L | | | | | | |
| D168N | | | | | | |
| D168R | | | | | | |
| D168T | | | | | | |
| D168V | | | | | | |
| D168Y | | | | | | |
| I170A | | | | | | |
| I170T | | | | | | |
| I170V | | | | | | |
| V36A+Q41R | | | | | | |
| V36A+T122N | | | | | | |
| V36M+R155K | | | | | | |
| Y56H+D168A | | | | | | |
| Y56H+D168V | | | | | | |
| T122N+D168A | | | | | | |
| Q41R+D168H | | | | | | |
| Q41R+D168A | | | | | | |
| Q41R+T122N | | | | | | |
| Q41R+D168Y | | | | | | |
| G50K+T122N | | | | | | |
Not indicated in Canada
Voxilaprevir
| Mutation | EC50 (nM) | Fold-shift | Phenotype | Clinical RAS | Reference | Replication Capacity (% WT) | Comments |
| WT (SA13) | 2.12 (SD 1.27) | 1x | likely susceptible | | 2 | 100 (3) | mean of 16 clinical isolates |
| V36M | | | | | | | |
| V36A | | | | | | | |
| V36L | | | | | | | |
| Q41R | unfit | | | | 2,3 | 0.9 (3) | |
| F43S | | | | | | | |
| T54A | | | | | | | |
| V55A | | | | | | | |
| Y56H | | | | | | | |
| Y56F | | | | | | | |
| Q80H | | | | | | | |
| Q80K | | | | | | | |
| Q80L | | | | | | | |
| Q80M | | | | | | | |
| Q80I | | | | | | | |
| Q80R | | | | | | | |
| V107I | | | | | | | |
| T122A | | | likely susceptible | | 2 | | |
| T122G | | | likely susceptible | | 2 | | |
| T122R | | | | | | | |
| T122V | | | likely susceptible | | 2 | | |
| R155G | unfit | | | | 2 | | |
| R155K | | | | | | | |
| R155T | | | | | | | |
| R155W | unfit | | | | 2 | | |
| A156G | unfit | | | | 2,1 | | VOX RAS (1) |
| A156S | | | | | 1 | | VOX RAS, >2.5x |
| A156T | unfit | | | | 2 | | |
| A156V | unfit | | | | 2 | | |
| A166S | | | likely susceptible | | 2 | | |
| D168A | | 8.1x | resistance possible | | 3,2,1 | 46.8 (3) | |
| D168E | | | likely susceptible | | 2,1 | | |
| D168F | | | | | | | |
| D168G | | | | | | | |
| D168H | | 11.6x | resistance likely | | 3,2,1 | 259 (3) | |
| D168I | | | | | | | |
| D168K | | 2.5-20x | resistance possible | | 2,1 | | |
| D168L | | | | | | | |
| D168N | | | | | | | |
| D168R | | 17.8x | resistance likely | | 3,2,1 | 3.1 (3) | |
| D168T | | | | | | | |
| D168V | | | likely susceptible | | 2 | | |
| D168Y | | 13.5x | resistance likely | | 3,2,1 | 404 (3) | |
| I170A | | | | | | | |
| I170T | | | | | | | |
| I170V | | | likely susceptible | | 2 | | |
| V36A+Q41R | unfit | | | | 2 | | |
| V36A+T122N | unfit | | | | 2 | | |
| V36M+R155K | | | | | | | |
| Y56H+D168A | | | | | | | |
| Y56H+D168V | | | | | | | |
| T122N+D168A | | 2.5-20x | resistance possible | | 2 | | |
| Q41R+D168H | | 35x | resistance likely | | 3,2 | 12.6 (3) | |
| Q41R+D168A | | 47x | resistance likely | | 3,2 | 24.1 (3) | |
| Q41R+T122N | unfit | | | | 2 | | |
| Q41R+D168Y | unfit | | | | 2 | 1.2 (3) | |
| G50K+T122N | unfit | | | | 2 | | |
| 1. Sarrazin C, et al. 2017. Gastroenterology 152: S1062 |
| 2. Dvory-Sobol H et al 2017 AASLD. http://www.natap.org/2017/AASLD/AASLD_29.htm |
| 3. FDA Vosevi Microbiology Reviews 209195Orig1s000MicroR |
